Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Generalized Myasthenia Gravis: later-stage trial registry
17 of 27 indexed Generalized Myasthenia Gravis trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #598 of 28,707 conditions by registered trial count.
27 US clinical trials · 17 currently recruiting · #598 of 28,707 conditions by registered trial count
Generalized Myasthenia Gravis: 27 US clinical trials tracked, 17 recruiting.
Generalized Myasthenia Gravis is the subject of 27 registered US clinical trials on ClinicalTrials.gov, 17 of them currently open to new participants. 15 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is argenx, running 7 of these trials.
Enrollment posture brief
Registry condition generalized-myasthenia-gravis
OPEN 17 | RECR 63% | LATE 15 | EARLY 9 | RANK #598 | SPON 7
Volume-matched condition peers
Nearest open-share peer: Caregiver Burden (63% recruiting · 43 trials)
Generalized Myasthenia Gravis lists 17 open slots (63% of 27 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Generalized Myasthenia Gravis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Generalized Myasthenia Gravis is recruiting above its size-band peers.
17 of 27 indexed trials (63%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Generalized Myasthenia Gravis research.
argenx accounts for 7 of 27 trials (25.9%). 12 distinct sponsors appear on at least one study for this condition label.
-
Typical Generalized Myasthenia Gravis enrolment sits around 70 participants.
Median target enrolment is 70 among the 27 trials that report a genuine target (sentinel values excluded). 14 of those (51.9%) plan for fewer than 100 participants.
-
Generalized Myasthenia Gravis research is mostly interventional.
25 interventional and 2 observational studies make up this index (92.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
27 total, page 1 of 1
Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
Alexion Pharmaceuticals
NCT04202341
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
NCT06463587
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
Immunovant Sciences
NCT07039916
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
Vor Biopharma
NCT06456580
A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
Novartis Pharmaceuticals
NCT06744920
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
Novartis Pharmaceuticals
NCT06517758
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
argenx
NCT07294170
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
argenx
NCT07284420
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
Kyverna Therapeutics
NCT06193889
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Myasthenia Gravis
University of Missouri-Columbia
NCT06064695
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Novartis Pharmaceuticals
NCT06704269
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Amgen
NCT06987539
Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
argenx
NCT04833894
A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia Gravis
UCB Biopharma SRL
NCT06149559
A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis
argenx
NCT06392386
PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis
Alexion Pharmaceuticals
NCT06607627
A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis
UCB Biopharma SRL
NCT06055959
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
Regeneron Pharmaceuticals
NCT05070858
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
Alexion Pharmaceuticals
NCT05556096
Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis
Immunovant Sciences
NCT05403541
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis
UCB Biopharma SRL
NCT04225871
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
argenx
NCT06298552
Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)
Alexion Pharmaceuticals
NCT05644561
A Study to Test Efficacy and Safety of Rozanolixizumab in Adult Patients With Generalized Myasthenia Gravis
UCB Biopharma SRL
NCT03971422
An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
argenx
NCT03669588
An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis
argenx
NCT04980495
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
Ra Pharmaceuticals
NCT03315130
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 8 |
| Phase 3 | 15 |
Top Sponsors
Named interventions
Most-linked intervention names on Generalized Myasthenia Gravis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Generalized Myasthenia Gravis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Generalized Myasthenia Gravis page
27 registered trials, 17 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 17 Generalized Myasthenia Gravis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- argenx sponsors the most Generalized Myasthenia Gravis trials on record, review their full trial history before evaluating a specific study. See argenx's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Generalized Myasthenia Gravis condition card totals 27 registered trials; most-linked intervention Efgartigimod IV; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.